Science1 hOctober 22, 2026, 13:01

FDA approves GSK's Hibsago, first hepatitis B drug with 'functional cure'

The FDA has approved GSK's Hibsago (bepirovirsen) injection for chronic hepatitis B. In the B-Well trials, 19% of patients achieved a functional cure after a six-month course, versus less than 1% on standard care.

New Atlas

Open source

FDA approves GSK's Hibsago, first hepatitis B drug with 'functional cure'

19% of patients achieved functional cure versus under 1% on standard care
Treatment lasts six months, with self-administration possible after the first dose
Approval granted under Priority Review and Breakthrough Therapy Designation
Chronic hepatitis B affects more than 250 million people worldwide

#GSK#FDA#Hibsago

FDA approves Zanvastro, first drug for Alexander disease

Science

FDA-approved epilepsy drug may reverse osteoarthritis cartilage damage

Science

FDA approves SELUTION SLR, first US sirolimus drug-eluting balloon for in-stent restenosis

Science

FDA approves GSK's Hibsago, first hepatitis B drug with 'functional cure'

FDA approves Zanvastro, first drug for Alexander disease

FDA-approved epilepsy drug may reverse osteoarthritis cartilage damage

FDA approves SELUTION SLR, first US sirolimus drug-eluting balloon for in-stent restenosis

AI designs functional enzyme components to aid drug discovery